Immunome, Inc. (IMNM) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.55: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 5.94; Below-average business quality.
Immunome is a clinical-stage oncology company with three clinical assets: varegacestat (Phase 3 RINGSIDE trial positive in desmoid tumors, NDA submission targeted Q2 2026), IM-1021 (ROR1 ADC in Phase 1), and IM-3050 (FAP-targeted radioligand therapy, Phase 1 initiation planned... Read more
Sell if holding. Engine safety override at $18.55: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 5.94; Below-average business quality. Chart setup: Oversold RSI 20, near Bollinger lower, volume surge. Score 5.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — Immunome, Inc.
Latest news
- NEWS Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target — benzinga Jun 12, 2026 positive
- NEWS Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid Tumors — benzinga Jun 11, 2026 positive
- NEWS Truist Securities Maintains Buy on Immunome, Raises Price Target to $37 — benzinga May 28, 2026 positive
- NEWS Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36 — benzinga May 28, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target — benzinga May 13, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinevaregacestat10-K Item 1: 'In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.55: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 5.94; Below-average business quality. Chart setup: Oversold RSI 20, near Bollinger lower, volume surge. Prior stop was $17.46. Score 5.2/10, moderate confidence.
Take-profit target: $30.76 (+67.5% upside). Prior stop was $17.46. Stop-loss: $17.46.
Concentration risk — Pipeline: varegacestat; Quality below floor (1.7 < 4.0).
Immunome, Inc. trades at a P/E of N/A (forward -8.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover IMNM with a consensus score of 4.2/5. Average price target: $35.
What does Immunome, Inc. do?Immunome is a clinical-stage oncology company with three clinical assets: varegacestat (Phase 3 RINGSIDE trial positive...
Immunome is a clinical-stage oncology company with three clinical assets: varegacestat (Phase 3 RINGSIDE trial positive in desmoid tumors, NDA submission targeted Q2 2026), IM-1021 (ROR1 ADC in Phase 1), and IM-3050 (FAP-targeted radioligand therapy, Phase 1 initiation planned 2026). The company has an accumulated deficit of $728.2M and no product revenues to date. Varegacestat was acquired from Ayala Pharmaceuticals in March 2024.